

INHIBITION OF POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE BY AMINOGLYCOSIDE ANTIBIOTICS*

LUCIO A. A. VAN ROOIJEN¹ AND BERNARD W. AGRANOFF²

*Neuroscience Laboratory
Mental Health Research Institute*

and

*Department of Biological Chemistry
The University of Michigan
1103 E. Huron
Ann Arbor, MI 48109*

Accepted September 5, 1984

The calcium-activated phosphodiesteratic hydrolysis of ³²P-labeled phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 4-phosphate in prelabeled nerve ending membranes is inhibited by the aminoglycosides neomycin and gentamicin, and to a lesser extent, by streptomycin. The inhibition is overcome by increasing concentrations of Ca²⁺, indicating that the aminoglycosides exert their effect by displacing Ca²⁺ from lipid.

INTRODUCTION

It has been known for some time that the aminoglycoside antibiotics bind tightly to polyphosphoinositides (1-3), and it has been proposed that their nephrotoxicity and ototoxicity may be related to their effects on the metabolism of these acidic lipids (4). It has previously been shown that these agents block phosphatidylinositol phosphate (PIP) kinase (5-7) and phosphatidylinositol 4,5-bisphosphate (PIP₂) and PIP monoesterase (5, 6, 8).

* Dedicated to Professor Yasuzo Tsukada.

¹ Present Address: Neurobiology Department, Troponwerke, Berliner Str. 156, 5000 Cologne 80, Federal Republic of Germany.

² To whom correspondence should be addressed.

Downes and Michell (9) demonstrated endogenous phosphodiesteratic activity in erythrocytes ghosts that cleaves PIP₂ and PIP in the presence of Ca²⁺, and that the degradation could be blocked by aminoglycosides. Membranes derived from nerve endings, which in contrast to erythrocytes, support ligand-activated stimulation of lipid labeling also have phosphodiesteratic activity against the polyphosphoinositides (10). Since there has been much recent interest in the receptor-mediated phosphodiesteratic cleavage of the polyphosphoinositides, particularly of PIP₂, to form diacylglycerol and inositol 1,4,5-trisphosphate (IP₃), we have examined the effects of aminoglycoside antibiotics on the activation by Ca²⁺ of the degradation of the polyphosphoinositides in prelabeled nerve ending membranes.

EXPERIMENTAL PROCEDURE

Membranes were prepared by sequential freezing, thawing and subsequent washing of nerve endings that had been prelabeled with ³²P_i (10). Following further preincubation for 15 min in bulk, aliquots of the labeled membranes (0.1–0.2 mg of protein) were incubated under various conditions for 5 min at 37°C with shaking, in a final volume of 0.25 ml of a buffer containing 30 mM HEPES/NaOH (pH 7.4) and 0.25 mM EGTA. The incubations were terminated by the addition of 1.5 ml of chloroform–methanol (1:2 by vol). Following extraction, lipids were separated by TLC, located autoradiographically, scraped and counted by liquid scintillation technique (10). Water-soluble compounds were separated on high voltage paper electrophoresis (pH 1.5). Bands, located by autoradiography, were cut out and counted (10, 11). Protein was determined spectrophotometrically (12).

RESULTS AND DISCUSSION

Addition of 1 mM neomycin or gentamicin to incubations of ³²P-prelabeled nerve ending membranes resulted in inhibition of the Ca²⁺-activated diesteratic degradation of both PIP₂ and PIP (Table I). Streptomycin appeared much less potent in inhibiting the breakdown. The relative degree of inhibition corresponds with the known ability of the various aminoglycosides to displace Ca²⁺ from synaptic membranes (13). Neomycin caused a 50% inhibition of PIP₂ and PIP breakdown at about 0.15 mM and 0.35 mM, respectively. This is consistent with the higher affinity of neomycin for PIP₂ than for PIP (1). Gentamicin also inhibited PIP₂ breakdown more effectively than that of PIP. In experiments on erythrocyte membranes in which only the release of IP₃ and inositol 1,4-bisphosphate (IP₂) were measured, Downes and Michell (9) obtained 50% inhibition at 1 and 7 mM neomycin, respectively. It should be noted in addition that

TABLE I
THE EFFECT OF AMINOGLYCOSIDES ON THE DIESTERATIC DEGRADATION OF
POLYPHOSPHOINOSITIDES

Aminoglycoside	Inhibition (%)	
	PIP ₂	PIP
Neomycin	80.5 ± 6.7	57.8 ± 2.7
Gentamicin	74.1 ± 3.2	46.5 ± 3.4
Streptomycin	28.1 ± 1.6	24.9 ± 0.7

Nerve ending membranes were incubated as described in the text, in the presence or absence of 0.4 mM free Ca²⁺ and 1 mM aminoglycoside as indicated. Since no significant effect of the aminoglycosides on radiotracer recovered as polyphosphoinositides was observed in the absence of Ca²⁺, these values were pooled. The values are expressed as percent inhibition of the Ca²⁺-induced loss of radiotracer, which was from 8716 ± 137 cpm (SEM, *n* = 12) in the absence of Ca²⁺ to 4648 ± 116 cpm (SEM, *n* = 3) in the presence of Ca²⁺ for PIP₂, and from 10076 ± 157 cpm (SEM, *n* = 12) to 5753 ± 177 cpm (SEM, *n* = 3) for PIP.

these authors employed a higher membrane concentration (2–2.5 mg/ml of protein) than used in the present study.

Ca²⁺ was required for the phosphodiesteratic degradation of the polyphosphoinositides, with an optimum in the region of 0.4–1.0 × 10⁻³ M (Figure 1). Higher concentrations of Ca²⁺ did not enhance further degradation of PIP and slightly inhibited PIP₂ breakdown. While concomitant release of the inositol phosphates could be observed, there also appeared to be breakdown of IP₃ to IP₂. This breakdown is known to be catalyzed by Mg²⁺ (14), and while it was not added, tightly bound Mg²⁺ may have nevertheless been present in the preparation. However, it should be noted that Mg²⁺-catalyzed monoesteratic degradation of PIP₂ and PIP is not found under these conditions (10). ATP, and its non-hydrolyzable analog, APPCP, at 1 mM concentrations, appeared to block IP₃ breakdown, possibly by chelation of the residual Mg²⁺. The nucleotides were not employed in the present study, since they precipitated neomycin. Neomycin itself appeared to inhibit degradation of IP₃ at higher Ca²⁺ levels. It can also be seen from Figure 1 that inhibition of the phosphodiesteratic activity by neomycin was most apparent at low [Ca²⁺] and that the effect of the aminoglycoside on lipid degradation could be abolished by increasing the concentration of the cation.

Studies of PIP kinase (5–7) and polyphosphoinositide monoesterases (5, 6, 8) as well as of phosphodiesteratic cleavage support the thesis that the aminoglycosides exert their effects by binding to the substrate rather than to the various enzymes. Although phosphatidylinositol binds ami-




FIG. 1. The effect of neomycin on the phosphodiesteratic degradation of the polyphosphoinositides PIP₂ and PIP to IP₃ and IP₂, respectively, activated by various concentrations of Ca²⁺. Nerve ending membranes were incubated as described in the text, in the presence (●) or absence (○) of 1 mM neomycin and various calculated concentrations (in EGTA buffer) of free Ca²⁺, as indicated. The incubations were terminated and the lipids and water-soluble compounds analyzed as described in the text. Each value represents the mean of duplicate determinations, from an experiment representative of 2–5 experiments.

noglycosides less tightly, similar observations have been made on the effects of aminoglycosides on the phosphodiesteratic breakdown of this lipid (15, 16). The present results are compatible with both the known binding of divalent cations to the polyphosphoinositides (17) and the requirement of Ca²⁺ for phosphodiesteratic cleavage. The aminoglycoside/Ca²⁺ ratio may then affect availability of the substrate for the phosphodiesterase, and might account for the lack of an effect by neomycin on Ca²⁺-activated erythrocyte polyphosphoinositide phosphodiesterase by Marche et al. (7), in which a neomycin/Ca²⁺ ratio of 0.3 was used in contrast to the results of Downes and Michell (9) who employed ratios of 2 and higher.

In the tissues in which ligand-stimulated degradation of polyphosphoinositides has been documented, there is preferential degradation of PIP₂ (18). Attempts with membrane preparations to demonstrate a differential susceptibility of the two polyphosphoinositides to Ca²⁺-activated phosphodiesteratic degradation do not yet permit discrimination of PIP₂ from

PIP breakdown (10). The availability of bound inositides to Ca^{2+} and aminoglycosides appear to be rather similar. While the present results suggest that PIP_2 in nerve ending membranes may bind Ca^{2+} somewhat better than PIP, the consequent effect on the diesteratic degradation does not appear to be sufficient to account for the observed difference in selectivity seen in ligand-stimulated degradation of PIP_2 in intact cells and Ca^{2+} -activated cleavage in membrane preparations.

ACKNOWLEDGMENTS

The authors thank Dr. Jochen Schacht for helpful discussions. This work was supported by NIH grant NS 15413.

REFERENCES

- SCHACHT, J. 1978. Purification of polyphosphoinositides by chromatography on immobilized neomycin. *J. Lipid Res.* 19:1063-1067.
- PALMER, F. B. St. C. 1981. Chromatography of acid phospholipids on immobilized neomycin. *J. Lipid Res.* 22:1296-1300.
- SASTRASINH, M., KNAUS, T. C., WEINBERG, J. M., and HUMES, H. D. 1982. Identification of aminoglycoside binding site in rat renal brush border membranes. *J. Pharmacol. Exp. Therap.* 222:350-358.
- HUMES, H. D., WEINER, N. D., and SCHACHT, J. 1982. The biochemical pathology of aminoglycoside-induced nephro- and ototoxicity. Pages 333-343, in FILLASTRE, J. P. (ed.), *Nephrotoxicity and Ototoxicity of Drugs*, INSERM, Paris.
- SCHACHT, J. 1976. Inhibition by neomycin of polyphosphoinositide turnover in subcellular fractions of guinea-pig cerebral cortex in vivo. *J. Neurochem.* 27:1119-1124.
- SCHIBECI, A., and SCHACHT, J. 1977. Action of neomycin on the metabolism of polyphosphoinositides in the guinea pig kidney. *Biochem. Pharmacol.* 26:1769-1774.
- MARCHE, P., KOUTOUZOV, S., and GIRARD, A. 1983. Impairment of membrane phosphoinositide metabolism by aminoglycoside antibiotics: streptomycin, amikacin, kanamycin, dibekacin, gentamicin and neomycin. *J. Pharmacol. Exp. Therap.* 227:415-420.
- ROACH, P. D., and PALMER, F. B. St. C. 1981. Human erythrocyte cytosol phosphatidylinositol-bisphosphate phosphatase. *Biochim. Biophys. Acta* 661:323-333.
- DOWNES, C. P., and MICHELL, R. H. 1981. The polyphosphoinositide phosphodiesterase of erythrocyte membranes. *Biochem. J.* 198:133-140.
- VAN ROOIJEN, L. A. A., SEGUIN, E. B., and AGRANOFF, B. W. 1983. Phosphodiesteratic breakdown of endogenous polyphosphoinositides in nerve ending membranes. *Biochem. Biophys. Res. Commun.* 112:919-926.
- SEIFFERT, U. B., and AGRANOFF, B. W. 1965. Isolation and separation of inositol phosphates from hydrolysates of rat tissues. *Biochim. Biophys. Acta* 98:574-581.
- BRADFORD, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72:248-254.

13. LODHI, S., WEINER, N. D., and SCHACHT, J. 1976. Interactions of neomycin and calcium in synaptosomal membranes and polyphosphoinositide monolayers. *Biochim. Biophys. Acta* 426:781-785.
14. DOWNES, C. P., MUSSAT, M. C., and MICHELL, R. H. 1982. The inositol trisphosphate phosphomonoesterase of the human erythrocyte membrane. *Biochem. J.* 203:169-177.
15. LIPSKY, J. J., and LIETMAN, P. S. 1982. Aminoglycoside inhibition of a renal phosphatidylinositol phospholipase C. *J. Pharmacol. Exp. Ther.* 220:287-292.
16. SAGAWA, N., BLEASDALE, J. E., and DI RENZO, G. C. 1983. The effects of polyamines and aminoglycosides on phosphatidylinositol-specific phospholipase C from human amnion. *Biochim. Biophys. Acta* 752:153-161.
17. HENDRICKSON, H. S., and REINERTSEN, J. L. 1969. Comparison of metal-binding properties of trans-1,2-cyclohexanediol diphosphate and deacylated phosphoinositides. *Biochem.* 8:4855-4858.
18. BERRIDGE, M. J. 1983. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyze polyphosphoinositides instead of phosphatidylinositol. *Biochem. J.* 212:849-858.